Form 4: Lyell COO Stephen Hill Granted 75,000 Stock Options

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, was granted 75,000 stock options with an exercise price of $17.23, vesting over approximately 3.5 years.

Summary

• Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc. (LYEL), was granted 75,000 stock options.
• The options have an exercise price of $17.23 per share.
• The transaction date for the option grant was October 27, 2025.
• The options will vest, with 12.5% vesting on April 27, 2026, and the remainder vesting in equal monthly installments over the subsequent 42 months, contingent on continued service.
• The options expire on October 26, 2035.
• Following this transaction, Mr. Hill beneficially owns 15,845 shares of common stock and 75,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management alignment with shareholder interests and incentivizing long-term performance. It's a standard compensation practice.

Positives

• The grant of 75,000 stock options to the Chief Operating Officer aligns management's interests with shareholder value.
• The vesting schedule incentivizes long-term commitment and performance from a key executive.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports an equity grant.

Risks

• The vesting of options is subject to the reporting person providing service through the applicable vesting date, meaning unvested options could be forfeited if employment ceases.
• The value of the options is dependent on the future stock price of Lyell Immunopharma, Inc. exceeding the exercise price of $17.23.

Future Outlook

The vesting schedule for the options extends over approximately 3.5 years, indicating an expectation of continued service from the Chief Operating Officer and a long-term incentive structure tied to future company performance.

Industry Context

Equity grants, particularly stock options with vesting schedules, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to align executive incentives with long-term shareholder value creation. This practice is common among companies like Lyell Immunopharma, which often rely on attracting and retaining key talent in a competitive R&D-intensive environment.

Comparison to Industry Standards

• The grant of stock options to a Chief Operating Officer is a standard compensation practice, comparable to similar grants observed at other biotech firms such as Moderna (MRNA) or BioNTech (BNTX) for their executives, where equity incentives are crucial for talent retention and performance alignment.
• The vesting schedule, with an initial cliff and subsequent monthly installments over several years, is a common structure designed to encourage long-term commitment, similar to those seen in executive compensation plans across the broader tech and healthcare sectors.
• The exercise price being at or above the market price on the grant date (implied by a typical option grant) is standard practice for incentive stock options, ensuring that the executive benefits only if the company's stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns the Chief Operating Officer's financial interests with long-term shareholder value creation, as the options gain value only if the stock price increases.
• Employees: This grant is part of executive compensation, potentially setting a precedent or standard for other equity-based incentives within the company.
• Management: The grant provides a significant incentive for the Chief Operating Officer to remain with the company and contribute to its growth over the vesting period.

Next Steps

• 12.5% of the granted options will vest on April 27, 2026.
• The remaining options will vest in equal monthly installments over the subsequent 42 months, subject to continued service.
• The Chief Operating Officer may exercise the vested options at the exercise price of $17.23 per share before the expiration date of October 26, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (option grant) and does not contain information that would fundamentally alter the investment thesis for Lyell Immunopharma. While it signals management alignment, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should continue to hold and evaluate the company based on its operational performance, clinical pipeline, and broader market conditions.

Keywords

Lyell Immunopharma, LYEL, Stephen J. Hill, Chief Operating Officer, stock options, equity grant, insider transaction, Form 4, executive compensation, vesting